Profile data is unavailable for this security.
About the company
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
- Revenue in USD (TTM)62.60m
- Net income in USD-120.74m
- Incorporated1998
- Employees61.00
- LocationNektar Therapeutics455 Mission Bay Boulevard SouthSAN FRANCISCO 94158United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.nektar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.19bn | 156.00 | -- | -- | -- | 851.74 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.25bn | 130.00 | -- | 5.00 | -- | 83.27 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.28bn | 73.00 | -- | 5.83 | -- | 202.29 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.32bn | 69.00 | -- | 2.57 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.35bn | 61.00 | -- | 15.33 | -- | 21.56 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.38bn | 147.00 | 75.67 | 4.77 | 47.22 | 7.62 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.39bn | 403.00 | -- | 1.86 | -- | 24.16 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.40bn | 123.00 | -- | 51.25 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.40bn | 3.00k | 48.70 | 0.8171 | 16.41 | 2.36 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.42bn | 26.00 | -- | 7.47 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.44bn | 54.00 | -- | 5.98 | -- | 476.97 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.46bn | 952.00 | 4.99 | -- | 3.87 | 1.37 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Alvotech SA | 573.35m | 69.50m | 1.51bn | 1.01k | 23.17 | -- | 14.39 | 2.64 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
Data as of Feb 12 2026. Currency figures normalised to Nektar Therapeutics's reporting currency: US Dollar USD
34.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2025 | 1.28m | 6.28% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 924.90k | 4.55% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 890.39k | 4.38% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 883.95k | 4.35% |
| Farallon Capital Management LLCas of 30 Sep 2025 | 791.00k | 3.89% |
| Millennium Management LLCas of 30 Sep 2025 | 545.99k | 2.68% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 476.31k | 2.34% |
| Two Sigma Investments LPas of 30 Sep 2025 | 434.24k | 2.14% |
| Nantahala Capital Management LLCas of 30 Sep 2025 | 418.52k | 2.06% |
| 22NW LPas of 30 Sep 2025 | 331.12k | 1.63% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
